Protein Kinase Inhibitors: all 15,278 studies that test it
Page 114 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.
- Study of Theliatinib (HMPL-309) in Patients With Advanced Solid TumorCompletedNCT02601248Phase 1
- Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast CancerCompletedNCT02599714Phase 1
- A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast CancerCompletedNCT02599363Phase 1
- Bioequivalence Study of Sorafenib Tablet and NexavarCompletedNCT02599337Phase 1
- Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or GliosarcomaWithdrawnNCT02599090Phase 2
- Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory LymphomaCompletedNCT02598570Phase 1
- Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)CompletedNCT02597322Phase 2
- Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade PineoblastomaCompletedNCT02596828Phase 2
- Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)Status unknownNCT02596256Phase 2
- M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT02595931Phase 1
- Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE)TerminatedNCT02595840Phase 2
- Dose Finding Trial of MK-7075 in Children and Adults With Proteus SyndromeCompletedNCT02594215Phase 1
- Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck CancerWithdrawnNCT02593929Early Phase 1
- Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+TerminatedNCT02593708Phase 1
- Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer PatientsCompletedNCT02593019Phase 2
- Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid TumorsCompletedNCT02592785Phase 1
- A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBCStatus unknownNCT02592746Phase 2
- Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine CancerCompletedNCT02592356Not applicable
- Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive TumorsActive, not recruitingNCT02592083Phase 2
- A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung CancerCompletedNCT02590965Phase 2
- A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid TumorsCompletedNCT02590952Phase 1
- Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine TumorsCompletedNCT02589821Phase 3
- Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)CompletedNCT02588677Phase 2/3
- Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine TumorsCompletedNCT02588170Phase 3
- Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced CancerCompletedNCT02588105Phase 1
- A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid TumoursCompletedNCT02586987Phase 1
- Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)CompletedNCT02586350Phase 2/3
- Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)Status unknownNCT02586337Phase 2/3
- Pharmacokinetics Study in Patients With Impaired Hepatic FunctionCompletedNCT02586194Phase 1
- Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCCCompletedNCT02585973Phase 1
- Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored StudyActive, not recruitingNCT02584933Phase 4
- A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in MyelofibrosisWithdrawnNCT02584777Phase 2
- Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)Active, not recruitingNCT02584478Phase 3
- REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological ProgressionCompletedNCT02584465Phase 2
- A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced CancersStatus unknownNCT02583542Phase 1/2
- Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic MelanomaCompletedNCT02583516Phase 2
- Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal DiseaseCompletedNCT02581124Phase 1
- Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT02580708Phase 1/2
- A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.CompletedNCT02579226Phase 1
- The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential ThrombocythemiaActive, not recruitingNCT02577926Phase 2
- Study of the Combination of CM082 With Everolimus in Patients With mRCCStatus unknownNCT02577458Phase 1
- A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsCompletedNCT02576431Phase 2
- A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)WithdrawnNCT02576275Phase 3
- A Study of [¹⁴C]-LY3023414 in Healthy ParticipantsCompletedNCT02575703Phase 1
- Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic CancerWithdrawnNCT02575508Phase 1/2
- Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma PatientsTerminatedNCT02575066Phase 2
- Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS TumorsActive, not recruitingNCT02574728Phase 2
- TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid TumorsCompletedNCT02574663Phase 1
- Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis PatientsCompletedNCT02574091Phase 1
- A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated LiposarcomaStatus unknownNCT02571829Phase 2
- A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215CompletedNCT02571816Phase 1
- A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced MalignanciesCompletedNCT02571036Phase 1
- PPI And Food Effect Study For PF-06463922 In Healthy VolunteersCompletedNCT02569554Phase 1
- Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth SyndromeWithdrawnNCT02569125Phase 2
- Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)Active, not recruitingNCT02568267Phase 2
- An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural PerspectiveCompletedNCT02566967Phase 3
- A Study To Investigate The Absorption, Distribution, Metabolism, And Excretion Of [14c]PF-06463922 In Healthy Male VolunteersCompletedNCT02564562Phase 1
- Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)WithdrawnNCT02564536Phase 1
- Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast CancerActive, not recruitingNCT02562118Phase 1/2
- (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid MalignanciesCompletedNCT02561988Phase 1
- AM-111 in the Treatment of Acute Inner Ear Hearing LossCompletedNCT02561091Phase 3
- Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid TumorsTerminatedNCT02559492Phase 1
- A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma PatientsCompletedNCT02558816Phase 1/2
- Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and NeckStatus unknownNCT02558387Phase 2
- Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)TerminatedNCT02558348Phase 1/2
- A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT02556892Phase 1
- IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain MetastasesTerminatedNCT02556593Phase 2
- Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell CarcinomaCompletedNCT02555748Phase 4
- Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic SyndromeCompletedNCT02553941Phase 1
- A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced CancersCompletedNCT02552953Phase 1
- A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell CarcinomaCompletedNCT02550678Phase 1/2
- To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine TherapyCompletedNCT02549430Phase 2
- Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerActive, not recruitingNCT02546661Phase 1
- Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced CancerCompletedNCT02546531Phase 1
- A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR PathwayCompletedNCT02544997Phase 2
- Apatinib for Metastatic Esophageal Cancer.Status unknownNCT02544737Phase 2
- Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular LymphomaCompletedNCT02542514Phase 2
- AMG 319 in HPV Positive and Negative HNSCCTerminatedNCT02540928Phase 2
- Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by SurgeryCompletedNCT02540876Phase 1
- Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung CancerStatus unknownNCT02540824Phase 2
- Relative Bioavailability of Sorafenib Tablet for Oral SuspensionCompletedNCT02538393Phase 1
- Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck CancerCompletedNCT02537223Phase 1
- Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric CancerStatus unknownNCT02537171Phase 3
- Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical ResectionStatus unknownNCT02537158Not applicable
- MSC2364447C Phase 1b in Systemic Lupus ErythematosusCompletedNCT02537028Phase 1
- A Study of LY3023414 in Japanese Participants With Advanced CancerCompletedNCT02536586Phase 1
- Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy SubjectsCompletedNCT02536391Phase 1
- Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus ErythematosusCompletedNCT02535689Phase 1
- Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung CancerStatus unknownNCT02535507Phase 2
- Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy VolunteersCompletedNCT02533102Phase 1
- A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)TerminatedNCT02532868Phase 1
- Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast CancerCompletedNCT02531932Phase 2
- Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung CancerCompletedNCT02531737Phase 2
- Bioequivalence Evaluation of a New and Current Tablet of ASP015KCompletedNCT02531191Phase 1
- "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "CompletedNCT02530424Phase 2
- Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast CancerStatus unknownNCT02530411Phase 2
- TACE With or Without Sorafenib in Intermediate Stage Hepatocellular CarcinomaStatus unknownNCT02529761Not applicable
- Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With MyelofibrosisWithdrawnNCT02528877Phase 1
- A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid LeukemiaWithdrawnNCT02527174Phase 1
- Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric CancerStatus unknownNCT02525237Phase 2